Moleculin receives approval to start trial of WP1122 for Covid-19 in UK
Moleculin Biotech has received authorisation to begin a Phase Ia clinical trial of its drug, WP1122, in the UK to treat Covid-19.
Moleculin Biotech has received authorisation to begin a Phase Ia clinical trial of its drug, WP1122, in the UK to treat Covid-19.
The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government.
Janssen-Cilag International, a subsidiary of Johnson & Johnson has submitted a conditional marketing authorisation application (cMAA) to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19 vaccine candidate.
The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to moderate Covid-19 patients.
Johnson & Johnson’s subsidiary Janssen Biotech has submitted an Emergency Use Authorization (EUA) application to the US Food and Drug Administration (FDA) for its investigational single-dose Janssen Covid-19 vaccine candidate.
AstraZeneca has secured a conditional marketing authorisation for its Covid-19 vaccine in the European Union (EU) for active immunisation in individuals aged 18 years and above.
The US Department of Defense (DOD) has approved the funding of US-based private pharmaceutical firm Humanetics to test its drug candidate BIO 300 in treating pulmonary inflammation triggered by COVID-19.
American pharma giant Merck has announced that it has discontinued the development of its SARS-CoV-2/Covid-19 vaccine candidates V590 and V591, after they performed poorly in phase 1 clinical trials.
Gritstone Oncology, a biotech firm developing vaccines, has announced that it is advancing the development of a second generation vaccine against Covid-19.
Dr. Reddy’s Laboratories has announced that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.